Shares of Immutep Ltd (NASDAQ:IMMP) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Analysts have set a 1-year consensus price target of $7.00 for the company, according to Zacks. Zacks has also assigned Immutep an industry rank of 98 out of 265 based on the ratings given to related companies.

Separately, Maxim Group reaffirmed a “buy” rating and set a $7.00 price objective on shares of Immutep in a research note on Thursday, November 9th.

Shares of Immutep (IMMP) traded up $0.11 during trading on Wednesday, reaching $1.87. The company had a trading volume of 26,600 shares, compared to its average volume of 81,261. Immutep has a twelve month low of $1.37 and a twelve month high of $3.26. The company has a debt-to-equity ratio of 0.22, a quick ratio of 6.06 and a current ratio of 6.06.

ILLEGAL ACTIVITY WARNING: “Brokerages Set $7.00 Target Price for Immutep Ltd (IMMP)” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at

Immutep Company Profile

Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.

Get a free copy of the Zacks research report on Immutep (IMMP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Immutep Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep Ltd and related companies with's FREE daily email newsletter.